REG - Assura plc - Result of AGM

AssuraAnnouncement

Today 15:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250930:nRSd4645Ba&default-theme=true

RNS Number : 4645B  Assura PLC  30 September 2025

30 September 2025

Assura plc ("Assura" or the "Company")

Result of AGM

 

Following its annual general meeting ("AGM") held today, Assura announces the
results of the poll vote for each of the resolutions submitted to the meeting
(as set out in the Notice of the AGM dated 5 September 2025). All resolutions
except for resolutions 13 to 16 were passed as Primary Health Properties PLC
decided they were not required at the current time.

 

 Resolution                                                                      For            %      Against        % Against  Total Votes Cast (% of issued share capital)  Votes Withheld

                                                                                                For
 1. To receive the Company's annual report and accounts                          3,191,210,029  99.92  2,702,703      0.08       3,193,912,732 (98.08)                         24,556
 2. To approve the Directors' Remuneration Policy                                3,191,198,870  99.92  2,713,862      0.08       3,193,912,732 (98.08)                         24,556
 3. To approve the Directors' Remuneration Report                                3,191,196,870  99.92  2,714,809      0.08       3,193,911,679 (98.08)                         25,609
 4. To re-appoint Ernst & Young LLP as auditor of the Company                    3,191,210,029  99.92  2,702,703      0.08       3,193,912,732 (98.08)                         24,556
 5. To authorise the Audit Committee to determine the auditor's remuneration     3,191,210,029  99.92  2,702,703      0.08       3,193,912,732 (98.08)                         24,556
 6. To re-elect Jonathan Murphy as a Director of the Company                     3,191,208,029  99.92  2,704,703      0.08       3,193,912,732 (98.08)                         24,556
 7. To re-elect Jayne Cottam as a Director of the Company                        3,191,208,029  99.92  2,704,703      0.08       3,193,912,732 (98.08)                         24,556
 8. To re-elect Louise Fowler as a Director of the Company                       3,190,442,909  99.89  3,469,823      0.11       3,193,912,732 (98.08)                         24,556
 9. To re-elect Jonathan Davies as a Director of the Company                     3,189,424,843  99.86  4,487,889      0.14       3,193,912,732 (98.08)                         24,556
 10. To re-elect Samantha Barrell as a Director of the Company                   3,190,440,909  99.89  3,471,823      0.11       3,193,912,732 (98.08)                         24,556
 11. To re-elect Emma Cariaga as a Director of the Company                       3,191,210,029  99.92  2,702,703      0.08       3,193,912,732 (98.08)                         24,556
 12. To re-elect Noel Gordon as a Director of the Company                        3,191,185,999  99.91  2,726,733      0.09       3,193,912,732 (98.08)                         24,556
 13. To authorise the Directors to allot shares                                  24,777,490     0.78   3,169,134,189  99.22      3,193,911,679 (98.08)                         25,609
 14. To authorise the Directors to disapply pre-emption rights                   13,632,718     0.43   3,180,279,914  99.57      3,193,912,632 (98.08)                         24,656
 15. To authorise the Directors to disapply pre-emption rights in connection     12,529,192     0.39   3,181,382,387  99.61      3,193,911,579 (98.08)                         25,709
 with an acquisition or specified capital investment
 16. To authorise the market purchase of the Company's own shares                25,792,609     0.81   3,168,120,123  99.19      3,193,912,732 (98.08)                         24,556
 17. To authorise re-registration of the Company as a private company and adopt  3,191,208,029  99.92  2,704,703      0.08       3,193,912,732 (98.08)                         24,556
 new articles of association
 18. To authorise the Company to call any general meeting, other than an annual  3,190,267,614  99.89  3,645,118      0.11       3,193,912,732 (98.08)                         24,556
 general meeting, by not less than 14 clear days' notice

Resolutions 1 to 12 were passed as ordinary resolutions. Resolutions 17 and 18
were passed as special resolutions. Votes 'For' include votes at the
discretion of the Chairman.

Notes:

1. The percentages above are rounded to two decimal places.

2. A vote withheld is not a vote in law and is not counted in the calculation
of the proportion of votes "For" and "Against" a resolution.

3. The total number of Assura ordinary shares in issue as at 6.00 pm on 26
September 2025, the time by which shareholders who wanted to vote at the AGM
must have been entered on the Company's register of members, was 3,256,393,191
and the total number of voting rights in the Company was also 3,256,393,191.

Copies of resolutions 17 and 18, being resolutions other than resolutions
concerning ordinary business passed by the Company at the above AGM, have been
submitted to the National Storage Mechanism and will shortly be available for
inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

- Ends -

For more information, please contact:

 Assura plc                                   Tel: 0161 515 2043
 Orla Ball, General Counsel                   Email: Investor@assura.co.uk

 David Purcell, Investor Relations Director

 FGS Global                                   Tel: 0207 251 3801

 Gordon Simpson                               Email: Assura-LON@fgsglobal.com

Grace Whelan

 

Notes to Editors

Assura is the UK's leading diversified healthcare REIT. Assura enables better
health outcomes through its portfolio of more than 600 healthcare buildings,
from which over six million patients are served.

A UK REIT based in Altrincham, Assura is currently a constituent of the EPRA*
index and has a secondary listing on the Johannesburg Stock Exchange. As at 31
March 2025, Assura's portfolio was valued at £3.1 billion and has a strong
track record of growing financial returns and dividends for shareholders.

At Assura we BUILD for health and as a certified B Corp we are committed to
keeping ESG as the heart of our strategy, creating Healthy Environments (E),
Healthy Communities (S) and maintaining a Healthy Business (G).

Further information is available at www.assuraplc.com

*EPRA is a registered trademark of the European Public Real Estate
Association.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSDEFDSEISELU